Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1269-1276

  Okada, S Steve ^a   Grobmyer, Stephen R ^a   Barnathan, Elliot S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

LDL receptor related protein; migration; plasminogen activators; smooth muscle cell; urokinase receptor

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; PLASMIN; PLASMINOGEN ACTIVATOR; UROKINASE;

ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INFILTRATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RECEPTOR BINDING; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0029799088     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1269     Document Type: Article

References (44)

1. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993;15:105-111.
2. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danq K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface plasmin dependent proteolysis. EMBO J. 1990;9:467-474.
3. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator, I: identity with annexin IL J Biol Chem. 1994;269:21191-21197.
4. Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1992;89:7427-7431.
5. Grobmyer SR, Kuo A, Orishimo M, Okada S, Cines DB, Barnathan ES. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem. 1993;268:13291-13300.
6. Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem. 1991;266:21232-21238.
7. 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem. 1994;268:21862-21867.
8. Okada SS, Tomaszewski JE, Barnathan ES. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp Cell Res. 1995;217:180-187.
9. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 1994;54:3066-3071.
10. Estreicher A, Muhlhauser J, Carpentier J-L, Orci L, Vassalli J-D. The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990;111:783-792.
11. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994;269:14746-14750.
12. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Proc Natl Acad Sci U S A. 1992;89:7422-7426.
13. Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA, Gliemann J. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex: evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992;267:14543-14546.
14. 2-Macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992;6:3345-3353.
15. Boudreau N, Turley E, Rabinovitch M. Fibronectin, hyaluronan, and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration. Dev Biol. 1991;143:235-247.
16. Todd RF II, Barnathan ES, Bohuslav J, et al. M16 CD87 cluster workshop report. In: Schlossman XX, et al. Leukocyte Typing V: White Cell Differentiation Antigens. Oxford, England: Oxford University Press; 1995.
17. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368:419-424.
18. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen. Plasminogen activator inhibitor-1 gene-deficient mice. I. J Clin Invest. 1993;92:2746-2755.
19. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995;9:794-807.
20. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Romer J, Solberg H, Ellis V, Dano K, Degen JL. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem. 1995;270:16886-16894.
21. Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann N Y Acad Sci. 1992;667:141-150.
22. Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB. Interaction of single chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem. 1990;265:2865-2872.
23. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J Clin Invest. 1993;91:1541-1552.
24. Del Rosso M, Anichini E, Pedersen N, Blasi F, Fibbi G, Pucci M, Ruggiero M. Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res Commun. 1993;190:347-352.
25. Odekon LE, Sato Y, Rifkin DB. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol. 1992;150:258-263.
26. Schnaper HW, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, Kleinman HK. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol. 1995;165:107-118.
27. Gyetko MR, Todd RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest. 1994;93:1380-1387.
28. Noda-Heiny H, Daugherty A, Sobel BE. Augmented urokinase receptor expression in atheroma. Arterioscler Thromb Vasc Biol. 1995;15:37-43.
29. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990;67:61-67.
30. Inyang AL, Tobelem G. Tissue-plasminogen activator stimulates endothelial cell migration in wound assay. Biochem Biophys Res Commun. 1990;171:1326-1332.
31. Herbert JM, Lamarche I, Prabonnaud V, Dol F, Gauthier T. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem. 1994;269:3076-3080.
32. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades u-PA/PAI-1 complexes and is essential for embryo implantation. Cell. 1992;71:411-421.
33. Herz J, Clouthier DE, Hammer RE. Correction: LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1993;72:428.
34. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papado-pouios N, Gluzband YA, Smith L, Weinstein C, Lakatta EG. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
35. Watanabe Y, Inaba T, Shimano H, Gotoda T, Yamamoto K, Mokuno H, Sato H, Yazaki Y, Yamada N. Induction of LDL receptor-related protein during the differentiation of monocyte-macrophages: possible involvement in the atherosclerotic process. Arterioscler Thromb. 1994;14:1000-1006.
36. 2-macroglobulin receptor in human normal and atherosclerotic arteries. Arterioslcer Thromb. 1994;14:1438-1444.
37. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalf JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Nature. 1994;370:460-462.
38. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-303.
39. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658.
40. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991;113:1439-1445.
41. Carmeliet P, Stassen JM, De Mol M, Bouche A, Collen D, Arterial neointima formation after trauma in mice with inactivation of the TPA, u-PA or PAI-1 genes. Circulation. 1994;90(pt 2):I-144. Abstract.
42. Ploplis VA. Plasminogen and plasminogen activator knockouts. Restenosis Summit. 1996;8:352-355.
43. Carmeliet P, Collen D. Role of the plasminogen plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis: evaluation in transgenic animals. Trends Cardiovasc Med. 1995;5:117-122.
44. Reidy MA, Irvin C, Lindner V. Migration of arterial-wall cells: expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res. 1996;78:405-414.